samedan logo
 
 
 
spacer
home > pmps > summer 2008 > free-flowing innovation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Free-Flowing Innovation

Interest in more advanced drug delivery systems has increased in line with the acceleration in the discovery and development of novel therapeutic macromolecules for targeted applications. Computational fluid dynamics (CFD) is a design tool that allows designers of these and other products to evaluate different designs rapidly and cost-effectively.

The use of CFD within the pharmaceutical industry has increased in recent years. Its application to the development of a new drug offers significant benefits in terms of yielding reduced costs, faster time to market, an improved understanding of existing or novel innovations, and the knowledge to make informed decisions to help guide and shape the direction of future research efforts.

These benefits are of particular significance in the search for an effective delivery system for a new drug – an issue that has become more pertinent in light of the recent moves away from needle- and syringe-based injection methods. Traditionally, animal experimentation has been used to evaluate drug delivery systems, but the results are not seen as sufficiently reliable when transposed to humans, whose respiratory physiology, for example, can differ greatly. This often leads to dramatically varying doses being realised from the same initial sample, making useful comparisons problematic.

In addition, an obligation exists under law to minimise experimentation on animals, placing restrictions on the level of testing that can be conducted. CFD can help overcome some of these issues, by allowing for the rapid and economic analysis of various drug delivery designs, using a three-dimensional model of human physiology.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Stephen Grant of ANSYS is an engineer with a degree in Manufacturing Systems. He has spent much of his career working in large scale production and manufacture in the automotive industry. He moved into a commercial role as a Systems Integrator looking after a broad range of industries from automotive and defence through to pharmaceutical. Stephen is now responsible for ANSYS’s development and growth in the healthcare sector across the UK.
spacer
Stephen Grant
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders

July 12, 2020 - The Data Demonstrating Benefits of Pharmacokinetic-Guided Prophylaxis Therapy in Hemophilia and von Willebrand Disease are Among 13 Presentations from Takeda’s Hematology Portfolio and Pipeline
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement